Internalization of targeted quantum dots by brain capillary endothelial cells in vivo

Receptors located on brain capillary endothelial cells forming the blood–brain barrier are the target of most brain drug delivery approaches. Yet, direct subcellular evidence of vectorized transport of nanoformulations into the brain is lacking. To resolve this question, quantum dots were conjugated to monoclonal antibodies (Ri7) targeting the murine transferrin receptor. Specific transferrin receptor-mediated endocytosis of Ri7-quantum dots was first confirmed in N2A and bEnd5 cells. After intravenous injection in mice, Ri7-quantum dots exhibited a fourfold higher volume of distribution in brain tissues, compared to controls. Immunofluorescence analysis showed that Ri7-quantum dots were sequestered throughout the cerebral vasculature 30 min, 1 h, and 4 h post injection, with a decline of signal intensity after 24 h. Transmission electron microscopic studies confirmed that Ri7-quantum dots were massively internalized by brain capillary endothelial cells, averaging 37 ± 4 Ri7-quantum dots/cell 1 h after injection. Most quantum dots within brain capillary endothelial cells were observed in small vesicles (58%), with a smaller proportion detected in tubular structures or in multivesicular bodies. Parenchymal penetration of Ri7-quantum dots was extremely low and comparable to control IgG. Our results show that systemically administered Ri7-quantum dots complexes undergo extensive endocytosis by brain capillary endothelial cells and open the door for novel therapeutic approaches based on brain endothelial cell drug delivery.

[1]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo , 2013 .

[2]  R. Watts,et al.  Bispecific antibodies for delivery into the brain. , 2013, Current opinion in chemical biology.

[3]  Mark E. Davis,et al.  Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor , 2013, Proceedings of the National Academy of Sciences.

[4]  Chu‐Fang Wang,et al.  The in vivo biodistribution and fate of CdSe quantum dots in the murine model: a laser ablation inductively coupled plasma mass spectrometry study , 2012, Analytical and Bioanalytical Chemistry.

[5]  H. Mizusawa,et al.  Efficient in vivo delivery of siRNA into brain capillary endothelial cells along with endogenous lipoprotein. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  F. Calon,et al.  In Vivo Labeling of Brain Capillary Endothelial Cells after Intravenous Injection of Monoclonal Antibodies Targeting the Transferrin Receptor , 2011, Molecular Pharmacology.

[7]  J. Leroux,et al.  siRNA nanocarriers based on methacrylic acid copolymers. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[8]  W. Luk,et al.  Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.

[9]  K. Scearce-Levie,et al.  A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.

[10]  Thomas Knobloch,et al.  Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB) , 2011, Journal of drug targeting.

[11]  L. Descarries,et al.  Distribution and ultrastructural features of the serotonin innervation in rat and squirrel monkey subthalamic nucleus , 2010, The European journal of neuroscience.

[12]  R. Gabathuler,et al.  Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases , 2010, Neurobiology of Disease.

[13]  J. Kreuter,et al.  Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[14]  R. Béliveau,et al.  Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2 , 2008, Journal of neurochemistry.

[15]  J. Nutt,et al.  Strategies to advance translational research into brain barriers , 2008, The Lancet Neurology.

[16]  E. Morgan,et al.  Iron trafficking inside the brain , 2007, Journal of neurochemistry.

[17]  W. Pardridge Brain Drug Development and Brain Drug Targeting , 2007, Pharmaceutical Research.

[18]  T. Maurer,et al.  Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios , 2007, Drug Metabolism and Disposition.

[19]  J. Haorah,et al.  Blood–brain Barrier: Structural Components and Function Under Physiologic and Pathologic Conditions , 2006, Journal of Neuroimmune Pharmacology.

[20]  Thomas J Deerinck,et al.  Correlated light and electron microscopic imaging of multiple endogenous proteins using Quantum dots , 2005, Nature Methods.

[21]  G. Storm,et al.  Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  P. Aisen,et al.  Transferrin receptor 1. , 2004, The international journal of biochemistry & cell biology.

[23]  T. Shimazoe,et al.  In vivo delivery of glial cell-derived neurotrophic factor across the blood-brain barrier by gene transfer into brain capillary endothelial cells. , 2003, Human gene therapy.

[24]  E. Cornford,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Delivery of Compounds across the Bbb: Strategies and Methods New Systems for Delivery of Drugs to the Brain in Neurological Disease , 2022 .

[25]  P. Stahl,et al.  Multivesicular Bodies and Multivesicular Endosomes: The "Ins and Outs" of Endosomal Traffic , 2002, Science's STKE.

[26]  E. Morgan,et al.  Restricted transport of anti‐transferrin receptor antibody (OX26) through the blood–brain barrier in the rat , 2001, Journal of neurochemistry.

[27]  W. Pardridge,et al.  Low blood–brain barrier permeability to azidothymidine (AZT), 3TC™, and thymidine in the rat , 1998, Brain Research.

[28]  U. Bickel,et al.  Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[29]  W. Pardridge,et al.  Transport of [125I]transferrin through the rat blood-brain barrier , 1995, Brain Research.

[30]  U. Bickel,et al.  In vivo demonstration of subcellular localization of anti-transferrin receptor monoclonal antibody-colloidal gold conjugate in brain capillary endothelium. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  R. Fine,et al.  Receptor-mediated endocytosis of transferrin at the blood-brain barrier. , 1993, Journal of cell science.

[32]  R. Starzyk,et al.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Giometto,et al.  Transferrin receptors in rat central nervous system An immunocytochemical study , 1990, Journal of the Neurological Sciences.

[34]  M. Bjorn,et al.  Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors. , 1987, Cancer research.

[35]  C. Harding,et al.  Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding. , 1984, European journal of cell biology.

[36]  P. Stahl,et al.  Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes , 1983, The Journal of cell biology.

[37]  加藤 伸吾 Organ distribution of quantum dots after intraperitoneal administration, with special reference to area-specific distribution in the brain , 2011 .

[38]  T. Nishizaki,et al.  Transferrin receptors in injured brain , 2004, Acta Neuropathologica.

[39]  R. Broadwell Transcytosis of macromolecules through the blood-brain barrier: a cell biological perspective and critical appraisal , 2004, Acta Neuropathologica.

[40]  F. Calon,et al.  Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. , 2003, Human gene therapy.

[41]  W. Oldendorf,et al.  The blood-brain barrier. , 1977, Experimental eye research.